SAN DIEGO, June 3, 2019 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that President and CEO Michael W. Nall is scheduled to present a
corporate overview at the 9th Annual LD Micro
Invitational Conference on Tuesday, June 4,
2019, at 10:00 a.m. Pacific
time (1:00 p.m. Eastern time).
The conference is being held at Luxe Sunset Boulevard Hotel in
Los Angeles.
A live webcast of the corporate presentation will be available
on the Company's website at ir.biocept.com. A replay of the
presentations will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the platform has
demonstrated the ability to identify cancer mutations and
alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please
visit www.biocept.com.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-at-the-9th-annual-ld-micro-invitational-conference-on-june-4-300860136.html
SOURCE Biocept, Inc.